Abstract
Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.
Original language | English (US) |
---|---|
Pages (from-to) | 1228-1232 |
Number of pages | 5 |
Journal | Movement Disorders |
Volume | 34 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2019 |
Keywords
- autopsy
- diversity
- phenotype
- progressive supranuclear palsy
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Movement Disorders, Vol. 34, No. 8, 08.2019, p. 1228-1232.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy
AU - for the Movement Disorder Society-endorsed PSP Study Group
AU - Grimm, Max Joseph
AU - Respondek, Gesine
AU - Stamelou, Maria
AU - Arzberger, Thomas
AU - Ferguson, Leslie
AU - Gelpi, Ellen
AU - Giese, Armin
AU - Grossman, Murray
AU - Irwin, David J.
AU - Pantelyat, Alexander
AU - Rajput, Alex
AU - Roeber, Sigrun
AU - van Swieten, John C.
AU - Troakes, Claire
AU - Antonini, Angelo
AU - Bhatia, Kailash P.
AU - Colosimo, Carlo
AU - van Eimeren, Thilo
AU - Kassubek, Jan
AU - Levin, Johannes
AU - Meissner, Wassilios G.
AU - Nilsson, Christer
AU - Oertel, Wolfgang H.
AU - Piot, Ines
AU - Poewe, Werner
AU - Wenning, Gregor K.
AU - Boxer, Adam
AU - Golbe, Lawrence I.
AU - Josephs, Keith A.
AU - Litvan, Irene
AU - Morris, Huw R.
AU - Whitwell, Jennifer L.
AU - Compta, Yaroslau
AU - Corvol, Jean Christophe
AU - Lang, Anthony E.
AU - Rowe, James B.
AU - Höglinger, Günter U.
N1 - Funding Information: Johannes Levin has received study support (third‐party funds) from Parkinson Fonds Deutschland gGmbH (a private organization that provides grants for research into Parkinson's disease), the Verum Foundation, the German Neurological Foundation (Deutsche Stiftung Neurologie), the German Parkinson Society and the Bischof Dr. Karl Golser Foundation and lecture fees from Bayer Healthcare as well as consulting fees from Hexal, Ionis Parmaceuticals and Axon Neuroscience. Funding Information: Jennifer L. Whitwell was supported by National Institutes of Health grants R01‐NS89757, R01‐DC12519, R01‐AG50603, R01‐AG37491, and R21‐NS94684. Funding Information: James B. Rowe is supported by the Wellcome Trust (103838) and has received additional research grant support from AZ‐Medimmune and Janssen, PSP Association, Medical Research Council, Wellcome Trust, National Institute for Health Research, McDonnell Foundation, Alzheimer Research UK, and Evelyn Trust; advised Asceneuron; and serves as Associate Editor at Brain. Funding Information: Huw Morris has received grants from Medical Research Council UK, Wellcome Trust, Parkinson's UK, Ipsen Fund, Motor Neurone Disease Association, Welsh Assembly Government, PSP Association, CBD Solutions and Drake Foundation, and payment for advisory work/consulting and lectures from Bristol‐Myers‐Squibb, GE‐HealthCare, Alzprotect, E‐Scape Bio, Teva, AbbVie, Boehringer Ingelheim, and GSK. Funding Information: Christer Nilsson has received research support from the Swedish Alzheimer Fund, Skåne University Hospital grants and the Swedish Research Council ALF grants. Funding Information: Alex Rajput has received research support from the Regina Curling Classic, Greystone Classic for Parkinson's, Inc. and the Dr. Ali Rajput Endowment for Parkinson's Disease and Movement Disorders; has been coinvestigator on grant funded by International Essential Tremor Foundation (study period 2012‐2013); has received research funding as principal investigator for the clinical study by Teva, protocol no.: TVP‐1012/501 (August 2009‐June 2013); has received speaker and travel honoraria from Teva, Allergan, and the Parkinson Society Canada. Funding Information: The project was supported by the Bischof Dr. Karl Golser Stiftung, CurePSP, Deutsche Forschungsgemeinschaft (DFG, HO 2402/11‐1), German Center for Neurodegenerative Diseases e.V. (DZNE), German PSP Gesellschaft, Tau Consortium, UK PSP Association, and the International Parkinson & Movement Disorder Society. Funding agencies: Funding Information: Gregor K. Wenning reports receiving consulting and/or lecture fees from Affiris, Astra Zeneca, Boehringer Ingelheim, Ever Pharma, Lundbeck, Neuropore, Orion, and UCB as well as grant support from Medical University Innsbruck, Oesterreichische Nationalbank, FWF Austrian Science Fund, US MSA Coalition, Affiris, Astra Zeneca, and Boehringer Ingelheim. Funding Information: Wassilios G Meissner has received fees for editorial activities with Springer, has served as advisor for Sanofi, Lundbeck and Affiris, has received teaching honoraria from TEVA, UCB, and Aguettant, as well as research support from the Michael J. Fox Foundation, the University Hospital Bordeaux, the French Health Ministry, the European Community, ANR, ARAMISE, PSP‐France, MSA Coalition, LABEX Excellence Initiative. Funding Information: Alexander Pantelyat was supported by NIH grant K23 AG059891. Funding Information: Kailash P Bhatia has received grant support from Welcome/MRC, NIHR, Parkinsons's UK and EU Horizon 2020. He has received honoraria/consulting fees for speaker‐related activities from Ipsen, Allergan, Merz, Sun Pharma, Teva, UCB pharma companies and from the American Academy of Neurology and Movement Disorders Society. He is an editor of journal and receives an honorary stipend from MDS for this activity and has received royalties for publications of the Oxford Specialist Handbook Parkinson's Disease (Oxford University Press, 2008, 2016) and of Marsden's Book of Movement Disorders from Oxford University Press. MDCP Funding Information: Wolfgang H. Oertel is Hertie Senior Research Professor supported by the Charitable Hertie Foundation, Frankfurt/Main. He has served as a consultant for Novartis, Schwarz Pharma and Neuroscience /UCB; has served on the advisory boards for Merck, Sharp & Dohme, Medtronic, Mundipharma, Novartis, Schwabe Pharma, Schwarz Pharma, Neuroscience/UCB, and Teva; has owned stocks of Roche 300 and Medigene 3000; has received speaker and travel honoraria from AbbVie, Desitin, GlaxoSmithKline, Mundipharma, Novartis, Schwarz Pharma Neuroscience/UCB, and Teva; has received research support from the German Ministry of Education and Health, IPF, and MJFF. Funding Information: Ellen Gelpi has received research support from the Fundació Marató de TV3 (grant 20141610), and Fundación Tatiana Pérez de Guzmán del Bueno; has served on the advisory board of the ICM Institute for Brain and Spinal Cord, Hopital Pitié Salpetrière, Paris, France, and the Oxford Parkinson Disease Center, Oxford, UK. Funding Information: David J Irwin is supported by National Institutes of Health grant K23 NS088341. Funding Information: Thilo van Eimeren is supported by grants of the Deutsche Forschungsgemeinschaft (DFG, EI 892/3‐1), the EU Joint Programme – Neurodegenerative Disease Research (JPND, Innofond 6177‐00001B) and the Leibniz Association (SAW‐2013‐IfW‐2) and received speaking honoraria and consulting fees from Eli Lily, Shire and the CHDI Foundation. Funding Information: Lawrence I. Golbe is supported by research funding from Bristol‐Myers Squibb, AbbVie and the American Parkinson's Disease Association and consults for Bristol‐Myers Squibb, AbbVie, SJO Research, and the University of California. Publisher Copyright: © 2019 International Parkinson and Movement Disorder Society
PY - 2019/8
Y1 - 2019/8
N2 - Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.
AB - Background: The Movement Disorder Society criteria for progressive supranuclear palsy define diagnostic allocations, stratified by certainty levels and clinical predominance types. We aimed to study the frequency of ambiguous multiple allocations and to develop rules to eliminate them. Methods: We retrospectively collected standardized clinical data by chart review in a multicenter cohort of autopsy-confirmed patients with progressive supranuclear palsy, to classify them by diagnostic certainty level and predominance type and to identify multiple allocations. Results: Comprehensive data were available from 195 patients. More than one diagnostic allocation occurred in 157 patients (80.5%). On average, 5.4 allocations were possible per patient. We developed four rules for Multiple Allocations eXtinction (MAX). They reduced the number of patients with multiple allocations to 22 (11.3%), and the allocations per patient to 1.1. Conclusions: The proposed MAX rules help to standardize the application of the Movement Disorder Society criteria for progressive supranuclear palsy.
KW - autopsy
KW - diversity
KW - phenotype
KW - progressive supranuclear palsy
UR - http://www.scopus.com/inward/record.url?scp=85067853775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067853775&partnerID=8YFLogxK
U2 - 10.1002/mds.27666
DO - 10.1002/mds.27666
M3 - Article
C2 - 30884545
AN - SCOPUS:85067853775
SN - 0885-3185
VL - 34
SP - 1228
EP - 1232
JO - Movement Disorders
JF - Movement Disorders
IS - 8
ER -